Drug-eluting Coronary Stents

نویسندگان
چکیده

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Drug-eluting coronary-artery stents.

n engl j med 368;16 nejm.org april 18, 2013 1557 by Barbui et al., a consensus statement of which they are coauthors, contains no data addressing their assertion because, as Barbui has written elsewhere,1 there are no data implicating the baseline leukocyte count as a thrombotic risk factor in patients with polycythemia vera. Fourth, by choosing the reference by Campbell et al., they are confla...

متن کامل

Drug-eluting coronary artery stents.

Many advances have been made in the percutaneous treatment of coronary artery disease during the past 30 years. Although balloon angioplasty alone is still performed, the use of coronary artery stents is much more common. Approximately 40 percent of patients treated with balloon angioplasty developed restenosis, and this was reduced to roughly 30 percent with the use of bare-metal stents. Howev...

متن کامل

Thrombosis in Coronary Drug-Eluting Stents

Coronary drug-eluting stents (DES) were first approved for use in the United States in 2003 (Cypher Coronary Sirolimus-Eluting Stent [SES], Cordis Corporation, Miami Lakes, Fla) and 2004 (Taxus Express Paclitaxel-Eluting Stent [PES], Boston Scientific Corporation, Natick, Mass) on the basis of randomized, blinded, controlled studies that demonstrated reduced target vessel failure (Cypher) and t...

متن کامل

Downstream coronary effects of drug-eluting stents.

BACKGROUND Antiproliferative agents used in drug-eluting stents (DES) attenuate atherosclerosis, yet DES implantation has been linked to endothelial dysfunction. The downstream effects of DES on new lesion formation have not been previously directly examined. We sought to compare the development of de novo stenoses and need for treatment in the downstream coronary vessel of patients treated wit...

متن کامل

Drug-Eluting Stents for Coronary Revascularization

NOTICE: Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc., provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criter...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Anesthesiology

سال: 2007

ISSN: 0003-3022

DOI: 10.1097/01.anes.0000265147.48449.03